NEW HAVEN, Conn., Aug. 22, 2007 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of David P. Wright to its Board of Directors. Mr. Wright, who is President and Chief Executive Officer of Pharmathene, Inc., brings extensive experience in pharmaceutical market development, product launch and commercial operations. He will serve on Achillion’s audit committee.
